Pardi, Norbert http://orcid.org/0000-0003-1008-6242
Carreño, Juan Manuel
O’Dell, George
Tan, Jessica http://orcid.org/0000-0001-8269-5560
Bajusz, Csaba
Muramatsu, Hiromi
Rijnink, Willemijn
Strohmeier, Shirin
Loganathan, Madhumathi http://orcid.org/0000-0002-3751-8036
Bielak, Dominika
Sung, Molly M. H. http://orcid.org/0000-0002-0874-0922
Tam, Ying K.
Krammer, Florian http://orcid.org/0000-0003-4121-776X
McMahon, Meagan http://orcid.org/0000-0002-7450-6624
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NIH R01-AI146101, NIH R01-AI146101)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (75N93019C00051)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 29 November 2021
Accepted: 20 July 2022
First Online: 9 August 2022
Competing interests
: In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that NP and YKT are named on a patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. NP and FK are named on a patent filed on universal influenza vaccines using nucleoside-modified mRNA. FK is also named on several patents and patent applications for universal influenza virus vaccine candidates based on other vaccine platforms. We have disclosed those interests fully to the University of Pennsylvania and The Icahn School of Medicine at Mount Sinai, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. MMHS and YKT are employees of Acuitas Therapeutics, a company focused on the development of LNP nucleic acid delivery systems for therapeutic applications. FK has consulted for Merck and Pfizer (before 2020) and currently consults for Pfizer, Seqirus, and Avimex. MM is now employed at Seqirus, Parkville, Australia. The remaining authors declare no competing interests.